BIIB-080

At the J.P. Morgan Healthcare Conference, Biogen executives discussed the pressure from investors for new deals amidst a declining stock price. They emphasized the company's focus on growth, scientific conviction, and strategic acquisitions, highlighting recent milestones and the disciplined approach to business development.

Johnson & Johnson's posdinemab, a monoclonal antibody targeting phosphorylated tau, has received FDA Fast Track designation for early Alzheimer's treatment.

The FDA has approved Ionis Pharmaceuticals' Tryngolza (olezarsen) as the first treatment for adults with familial chylomicronemia syndrome (FCS).

Several cell and gene therapies are under investigation for Alzheimer's disease, with some showing early signs of efficacy in clinical trials.

Eisai initiates a rolling submission to the FDA for a subcutaneous formulation of Lecanemab (Leqembi) for weekly maintenance dosing in early Alzheimer's disease.